FDA issues Class I update on robotic arms due to risk of fire

The U.S. Food and Drug Administration (FDA) has issued an urgent correction for the safety instructions on Kinova robotic arms due to a risk of electrical fire caused by damage to a protective coating. If the exposed metal of the robotic arm touches an electric wheelchair, it could damage the device and put the user at serious risk for burns or death.

While there have been no reported injuries, the FDA has labeled this recall a Class I, the most serious designation. 

The Kinova Jaco Assistive Robotic Arm is used by people who have lost functionality of their arms, allowing the user to interact with objects. They are typically installed on one side of a motorized wheelchair, linked into the wheelchair's control stick. Despite the potential risks, the robots do not need to be removed from the market—people are free to continue using them, as long as they're inspected for safety.

What products are affected?

Jaco Assistive Robotic Arms
Kinova Jaco Assistive Robotic Arm installed on an electric wheelchair.

Jaco Assistive Robotic Arms with the following model numbers could potentially have life-threatening damage to their protective coating from normal use:

  • PJ 0000 0001
  • PJ 0000 0012
  • PJ 0090 0001
  • PJ 0090 0006
  • KR MJ2 0001 

The serial number is irrelevant, as all lots of the above models will need to be inspected by users. 

Next steps

Users and their caretakers must inspect Jaco Arms for missing parts, scratches, chips, cracks, nicks, dings—any visible damage to the outer coating of the arm could be dangerous. Unplug the robotic arm and cease its use if any defect is identified. 

If there is even minor visible damage, users should contact Kinova customer service immediately at 514-277-3777 ext. 2 or support@kinova.ca to have a protective pad installed. 

The updated user guide can be found here. Customers may contact Kinova to receive a print copy. 

The full FDA recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.